References
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934.
Sattar N, Taskinen MR. Statins are diabetogenic–myth or reality? Atheroscler Suppl. 2012;13(1):1–10.
Betteridge DJ, Carmena R. The diabetogenic action of statins - mechanisms and clinical implications. Nat Rev Endocrinol. 2016;12(2):99–110.
Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111(8):1123–30.
Zhang J, Shao Y, Liu Y, Tao J. A multi-center, open-label, two-arm parallel group non-inferiority randomized controlled trial evaluating the effect of pitavastatin, compared to atorvastatin, on glucose metabolism in prediabetics with hypertension and dyslipidemia: rationale and design for the China hemoglobin A1c metabolism protection union study (CAMPUS). Cardiovasc Drugs Ther. 2018;32(6):581–9.
Prevention or delay of type 2 diabetes: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S29–S33.
Zhao W, Zhao SP. Different effects of statins on induction of diabetes mellitus: an experimental study. Drug Des Devel Ther. 2015;9:6211–23.
Nakagomi A, Shibui T, Kohashi K, Kosugi M, Kusama Y, Atarashi H, et al. Differential effects of atorvastatin and pitavastatin on inflammation, insulin resistance, and the carotid intima-media thickness in patients with dyslipidemia. J Atheroscler Thromb. 2015;22(11):1158–71.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tao, J. Response Letter to Letter by Venu Jonnalagadda. Cardiovasc Drugs Ther 33, 765–766 (2019). https://doi.org/10.1007/s10557-019-06897-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-019-06897-7